APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Systemic Sclerosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Systemic Sclerosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174039370326 December 2025192 pages

Choose your research edition.

Industry ResearchSystemic Sclerosis Drug Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Systemic Sclerosis Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Systemic Sclerosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Systemic Sclerosis Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Systemic Sclerosis Drug Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Systemic Sclerosis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Systemic Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Systemic Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Systemic Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Systemic Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Systemic Sclerosis Drug include GlaxoSmithKline Plc, Bayer AG, GenKyoTex S.A., Fibrocell Science, Inc., F. Hoffmann-La Roche Ltd., Digna Biotech, S.L., Daval International Limited, CSL Limited and Corbus pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Systemic Sclerosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Systemic Sclerosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Systemic Sclerosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Systemic Sclerosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Systemic Sclerosis Drug Segment by Company

GlaxoSmithKline Plc

Bayer AG

GenKyoTex S.A.

Fibrocell Science, Inc.

F. Hoffmann-La Roche Ltd.

Digna Biotech, S.L.

Daval International Limited

CSL Limited

Corbus pharmaceuticals, Inc.

Bristol-Myers Squibb Company

Boehringer Ingelheim GmbH

BiOrion Technologies B.V.

BioLineRx, Ltd.

arGentis Pharmaceuticals, LLC

Angion Biomedica Corp.

Allergan Plc

Systemic Sclerosis Drug Segment by Type

ARG-201

BL-1110

BOT-191

C-82

Belimumab

Others

Systemic Sclerosis Drug Segment by Application

Clinic

Hospital

ASCs

Others

Systemic Sclerosis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Systemic Sclerosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Systemic Sclerosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Systemic Sclerosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Systemic Sclerosis Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Systemic Sclerosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Systemic Sclerosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Systemic Sclerosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Systemic Sclerosis Drug Industry Trends Table 2. Systemic Sclerosis Drug Industry Drivers Table 3. Systemic Sclerosis Drug Industry Opportunities and Challenges Table 4. Systemic Sclerosis Drug Industry Restraints Table 5. Global Systemic Sclerosis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Systemic Sclerosis Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Systemic Sclerosis Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Systemic Sclerosis Drug Sales Market Share by Manufacturers Table 9. Global Systemic Sclerosis Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Systemic Sclerosis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Systemic Sclerosis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Systemic Sclerosis Drug Manufacturers, Product Type & Application Table 13. Global Systemic Sclerosis Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Systemic Sclerosis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of ARG-201 Table 17. Major Manufacturers of BL-1110 Table 18. Major Manufacturers of BOT-191 Table 19. Major Manufacturers of C-82 Table 20. Major Manufacturers of Belimumab Table 21. Major Manufacturers of Others Table 22. Global Systemic Sclerosis Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Systemic Sclerosis Drug Sales by Type (2021-2026) & (W Units) Table 24. Global Systemic Sclerosis Drug Sales by Type (2027-2032) & (W Units) Table 25. Global Systemic Sclerosis Drug Sales Market Share by Type (2021-2026) Table 26. Global Systemic Sclerosis Drug Sales Market Share by Type (2027-2032) Table 27. Global Systemic Sclerosis Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 28. Global Systemic Sclerosis Drug Revenue by Type (2021-2026) & (W Units) Table 29. Global Systemic Sclerosis Drug Revenue by Type (2027-2032) & (W Units) Table 30. Global Systemic Sclerosis Drug Revenue Market Share by Type (2021-2026) Table 31. Global Systemic Sclerosis Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of ASCs Table 35. Major Manufacturers of Others Table 36. Global Systemic Sclerosis Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Systemic Sclerosis Drug Sales by Application (2021-2026) & (W Units) Table 38. Global Systemic Sclerosis Drug Sales by Application (2027-2032) & (W Units) Table 39. Global Systemic Sclerosis Drug Sales Market Share by Application (2021-2026) Table 40. Global Systemic Sclerosis Drug Sales Market Share by Application (2027-2032) Table 41. Global Systemic Sclerosis Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 42. Global Systemic Sclerosis Drug Revenue by Application (2021-2026) & (W Units) Table 43. Global Systemic Sclerosis Drug Revenue by Application (2027-2032) & (W Units) Table 44. Global Systemic Sclerosis Drug Revenue Market Share by Application (2021-2026) Table 45. Global Systemic Sclerosis Drug Revenue Market Share by Application (2027-2032) Table 46. Global Systemic Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 47. Global Systemic Sclerosis Drug Sales by Region (2021-2026) & (W Units) Table 48. Global Systemic Sclerosis Drug Sales Market Share by Region (2021-2026) Table 49. Global Systemic Sclerosis Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 50. Global Systemic Sclerosis Drug Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Systemic Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. North America Systemic Sclerosis Drug Sales by Country (2021-2026) & (W Units) Table 53. North America Systemic Sclerosis Drug Sales by Country (2027-2032) & (W Units) Table 54. Europe Systemic Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Europe Systemic Sclerosis Drug Sales by Country (2021-2026) & (W Units) Table 56. Europe Systemic Sclerosis Drug Sales by Country (2027-2032) & (W Units) Table 57. Asia Pacific Systemic Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Asia Pacific Systemic Sclerosis Drug Sales by Country (2021-2026) & (W Units) Table 59. Asia Pacific Systemic Sclerosis Drug Sales by Country (2027-2032) & (W Units) Table 60. South America, Middle East and Africa Systemic Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 61. South America, Middle East and Africa Systemic Sclerosis Drug Sales by Country (2021-2026) & (W Units) Table 62. South America, Middle East and Africa Systemic Sclerosis Drug Sales by Country (2027-2032) & (W Units) Table 63. Global Systemic Sclerosis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Systemic Sclerosis Drug Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Systemic Sclerosis Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Systemic Sclerosis Drug Revenue Market Share by Region (2021-2026) Table 67. Global Systemic Sclerosis Drug Revenue Market Share by Region (2027-2032) Table 68. GlaxoSmithKline Plc Company Information Table 69. GlaxoSmithKline Plc Business Overview Table 70. GlaxoSmithKline Plc Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. GlaxoSmithKline Plc Systemic Sclerosis Drug Product Portfolio Table 72. GlaxoSmithKline Plc Recent Development Table 73. Bayer AG Company Information Table 74. Bayer AG Business Overview Table 75. Bayer AG Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Bayer AG Systemic Sclerosis Drug Product Portfolio Table 77. Bayer AG Recent Development Table 78. GenKyoTex S.A. Company Information Table 79. GenKyoTex S.A. Business Overview Table 80. GenKyoTex S.A. Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. GenKyoTex S.A. Systemic Sclerosis Drug Product Portfolio Table 82. GenKyoTex S.A. Recent Development Table 83. Fibrocell Science, Inc. Company Information Table 84. Fibrocell Science, Inc. Business Overview Table 85. Fibrocell Science, Inc. Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Fibrocell Science, Inc. Systemic Sclerosis Drug Product Portfolio Table 87. Fibrocell Science, Inc. Recent Development Table 88. F. Hoffmann-La Roche Ltd. Company Information Table 89. F. Hoffmann-La Roche Ltd. Business Overview Table 90. F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product Portfolio Table 92. F. Hoffmann-La Roche Ltd. Recent Development Table 93. Digna Biotech, S.L. Company Information Table 94. Digna Biotech, S.L. Business Overview Table 95. Digna Biotech, S.L. Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Digna Biotech, S.L. Systemic Sclerosis Drug Product Portfolio Table 97. Digna Biotech, S.L. Recent Development Table 98. Daval International Limited Company Information Table 99. Daval International Limited Business Overview Table 100. Daval International Limited Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Daval International Limited Systemic Sclerosis Drug Product Portfolio Table 102. Daval International Limited Recent Development Table 103. CSL Limited Company Information Table 104. CSL Limited Business Overview Table 105. CSL Limited Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. CSL Limited Systemic Sclerosis Drug Product Portfolio Table 107. CSL Limited Recent Development Table 108. Corbus pharmaceuticals, Inc. Company Information Table 109. Corbus pharmaceuticals, Inc. Business Overview Table 110. Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product Portfolio Table 112. Corbus pharmaceuticals, Inc. Recent Development Table 113. Bristol-Myers Squibb Company Company Information Table 114. Bristol-Myers Squibb Company Business Overview Table 115. Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Bristol-Myers Squibb Company Systemic Sclerosis Drug Product Portfolio Table 117. Bristol-Myers Squibb Company Recent Development Table 118. Boehringer Ingelheim GmbH Company Information Table 119. Boehringer Ingelheim GmbH Business Overview Table 120. Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product Portfolio Table 122. Boehringer Ingelheim GmbH Recent Development Table 123. BiOrion Technologies B.V. Company Information Table 124. BiOrion Technologies B.V. Business Overview Table 125. BiOrion Technologies B.V. Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. BiOrion Technologies B.V. Systemic Sclerosis Drug Product Portfolio Table 127. BiOrion Technologies B.V. Recent Development Table 128. BioLineRx, Ltd. Company Information Table 129. BioLineRx, Ltd. Business Overview Table 130. BioLineRx, Ltd. Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. BioLineRx, Ltd. Systemic Sclerosis Drug Product Portfolio Table 132. BioLineRx, Ltd. Recent Development Table 133. arGentis Pharmaceuticals, LLC Company Information Table 134. arGentis Pharmaceuticals, LLC Business Overview Table 135. arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product Portfolio Table 137. arGentis Pharmaceuticals, LLC Recent Development Table 138. Angion Biomedica Corp. Company Information Table 139. Angion Biomedica Corp. Business Overview Table 140. Angion Biomedica Corp. Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Angion Biomedica Corp. Systemic Sclerosis Drug Product Portfolio Table 142. Angion Biomedica Corp. Recent Development Table 143. Allergan Plc Company Information Table 144. Allergan Plc Business Overview Table 145. Allergan Plc Systemic Sclerosis Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Allergan Plc Systemic Sclerosis Drug Product Portfolio Table 147. Allergan Plc Recent Development Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Systemic Sclerosis Drug Distributors List Table 151. Systemic Sclerosis Drug Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Systemic Sclerosis Drug Product Image Figure 2. Global Systemic Sclerosis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Systemic Sclerosis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Systemic Sclerosis Drug Sales (2021-2032) & (W Units) Figure 5. Global Systemic Sclerosis Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Systemic Sclerosis Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. ARG-201 Image Figure 9. BL-1110 Image Figure 10. BOT-191 Image Figure 11. C-82 Image Figure 12. Belimumab Image Figure 13. Others Image Figure 14. Global Systemic Sclerosis Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Systemic Sclerosis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Systemic Sclerosis Drug Sales Market Share by Type (2021-2032) Figure 17. Global Systemic Sclerosis Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Systemic Sclerosis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Systemic Sclerosis Drug Revenue Market Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. ASCs Image Figure 23. Others Image Figure 24. Global Systemic Sclerosis Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Systemic Sclerosis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Systemic Sclerosis Drug Sales Market Share by Application (2021-2032) Figure 27. Global Systemic Sclerosis Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 28. Global Systemic Sclerosis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Systemic Sclerosis Drug Revenue Market Share by Application (2021-2032) Figure 30. North America Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 31. North America Systemic Sclerosis Drug Sales Market Share by Country (2021-2032) Figure 32. U.S. Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Canada Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Mexico Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Europe Systemic Sclerosis Drug Sales Market Share by Country (2021-2032) Figure 37. Germany Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. France Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. U.K. Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Italy Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Netherlands Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Asia Pacific Systemic Sclerosis Drug Sales Market Share by Country (2021-2032) Figure 44. China Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Japan Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. South Korea Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Southeast Asia Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. India Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Australia Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South America, Middle East and Africa Systemic Sclerosis Drug Sales Market Share by Country (2021-2032) Figure 52. Brazil Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. South Africa Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Saudi Arabia Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Turkey Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Argentina Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. UAE Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Egypt Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Chile Systemic Sclerosis Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 60. Global Systemic Sclerosis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Systemic Sclerosis Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Systemic Sclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 63. North America Systemic Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Systemic Sclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 65. Europe Systemic Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Systemic Sclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Systemic Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Systemic Sclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Systemic Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Systemic Sclerosis Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Systemic Sclerosis Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • ARG-201
  • BL-1110
  • BOT-191
  • C-82
  • Belimumab
  • Others
Applications
  • Clinic
  • Hospital
  • ASCs
  • Others
Companies covered
  • GlaxoSmithKline Plc
  • Bayer AG
  • GenKyoTex S.A.
  • Fibrocell Science, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Digna Biotech, S.L.
  • Daval International Limited
  • CSL Limited
  • Corbus pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • BiOrion Technologies B.V.
  • BioLineRx, Ltd.
  • arGentis Pharmaceuticals, LLC
  • Angion Biomedica Corp.
  • Allergan Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Systemic Sclerosis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Systemic Sclerosis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Systemic Sclerosis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Systemic Sclerosis Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Systemic Sclerosis Drug Market Dynamics
  1. 2.1 Systemic Sclerosis Drug Industry Trends
  2. 2.2 Systemic Sclerosis Drug Industry Drivers
  3. 2.3 Systemic Sclerosis Drug Industry Opportunities and Challenges
  4. 2.4 Systemic Sclerosis Drug Industry Restraints
3 Systemic Sclerosis Drug Market by Manufacturers
  1. 3.1 Global Systemic Sclerosis Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Systemic Sclerosis Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Systemic Sclerosis Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Systemic Sclerosis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Systemic Sclerosis Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Systemic Sclerosis Drug Manufacturers, Product Type & Application
  7. 3.7 Global Systemic Sclerosis Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Systemic Sclerosis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Systemic Sclerosis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Systemic Sclerosis Drug Tier 1, Tier 2, and Tier 3
4 Systemic Sclerosis Drug Market by Type
  1. 4.1 Systemic Sclerosis Drug Type Introduction
  2. 4.1.1 ARG-201
  3. 4.1.2 BL-1110
  4. 4.1.3 BOT-191
  5. 4.1.4 C-82
  6. 4.1.5 Belimumab
  7. 4.1.6 Others
  8. 4.2 Global Systemic Sclerosis Drug Sales by Type
  9. 4.2.1 Global Systemic Sclerosis Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Systemic Sclerosis Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Systemic Sclerosis Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Systemic Sclerosis Drug Revenue by Type
  13. 4.3.1 Global Systemic Sclerosis Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Systemic Sclerosis Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Systemic Sclerosis Drug Revenue Market Share by Type (2021-2032)
5 Systemic Sclerosis Drug Market by Application
  1. 5.1 Systemic Sclerosis Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 ASCs
  5. 5.1.4 Others
  6. 5.2 Global Systemic Sclerosis Drug Sales by Application
  7. 5.2.1 Global Systemic Sclerosis Drug Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Systemic Sclerosis Drug Sales by Application (2021-2032)
  9. 5.2.3 Global Systemic Sclerosis Drug Sales Market Share by Application (2021-2032)
  10. 5.3 Global Systemic Sclerosis Drug Revenue by Application
  11. 5.3.1 Global Systemic Sclerosis Drug Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Systemic Sclerosis Drug Revenue by Application (2021-2032)
  13. 5.3.3 Global Systemic Sclerosis Drug Revenue Market Share by Application (2021-2032)
6 Global Systemic Sclerosis Drug Sales by Region
  1. 6.1 Global Systemic Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Systemic Sclerosis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Systemic Sclerosis Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Systemic Sclerosis Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Systemic Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Systemic Sclerosis Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Systemic Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Systemic Sclerosis Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Systemic Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Systemic Sclerosis Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Systemic Sclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Systemic Sclerosis Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Systemic Sclerosis Drug Revenue by Region
  1. 7.1 Global Systemic Sclerosis Drug Revenue by Region
  2. 7.1.1 Global Systemic Sclerosis Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Systemic Sclerosis Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Systemic Sclerosis Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Systemic Sclerosis Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Systemic Sclerosis Drug Revenue (2021-2032)
  8. 7.2.2 North America Systemic Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Systemic Sclerosis Drug Revenue (2021-2032)
  11. 7.3.2 Europe Systemic Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Systemic Sclerosis Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Systemic Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Systemic Sclerosis Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Systemic Sclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GlaxoSmithKline Plc
  2. 8.1.1 GlaxoSmithKline Plc Company Information
  3. 8.1.2 GlaxoSmithKline Plc Business Overview
  4. 8.1.3 GlaxoSmithKline Plc Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GlaxoSmithKline Plc Systemic Sclerosis Drug Product Portfolio
  6. 8.1.5 GlaxoSmithKline Plc Recent Developments
  7. 8.2 Bayer AG
  8. 8.2.1 Bayer AG Company Information
  9. 8.2.2 Bayer AG Business Overview
  10. 8.2.3 Bayer AG Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer AG Systemic Sclerosis Drug Product Portfolio
  12. 8.2.5 Bayer AG Recent Developments
  13. 8.3 GenKyoTex S.A.
  14. 8.3.1 GenKyoTex S.A. Company Information
  15. 8.3.2 GenKyoTex S.A. Business Overview
  16. 8.3.3 GenKyoTex S.A. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GenKyoTex S.A. Systemic Sclerosis Drug Product Portfolio
  18. 8.3.5 GenKyoTex S.A. Recent Developments
  19. 8.4 Fibrocell Science, Inc.
  20. 8.4.1 Fibrocell Science, Inc. Company Information
  21. 8.4.2 Fibrocell Science, Inc. Business Overview
  22. 8.4.3 Fibrocell Science, Inc. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Fibrocell Science, Inc. Systemic Sclerosis Drug Product Portfolio
  24. 8.4.5 Fibrocell Science, Inc. Recent Developments
  25. 8.5 F. Hoffmann-La Roche Ltd.
  26. 8.5.1 F. Hoffmann-La Roche Ltd. Company Information
  27. 8.5.2 F. Hoffmann-La Roche Ltd. Business Overview
  28. 8.5.3 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 F. Hoffmann-La Roche Ltd. Systemic Sclerosis Drug Product Portfolio
  30. 8.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
  31. 8.6 Digna Biotech, S.L.
  32. 8.6.1 Digna Biotech, S.L. Company Information
  33. 8.6.2 Digna Biotech, S.L. Business Overview
  34. 8.6.3 Digna Biotech, S.L. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Digna Biotech, S.L. Systemic Sclerosis Drug Product Portfolio
  36. 8.6.5 Digna Biotech, S.L. Recent Developments
  37. 8.7 Daval International Limited
  38. 8.7.1 Daval International Limited Company Information
  39. 8.7.2 Daval International Limited Business Overview
  40. 8.7.3 Daval International Limited Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Daval International Limited Systemic Sclerosis Drug Product Portfolio
  42. 8.7.5 Daval International Limited Recent Developments
  43. 8.8 CSL Limited
  44. 8.8.1 CSL Limited Company Information
  45. 8.8.2 CSL Limited Business Overview
  46. 8.8.3 CSL Limited Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CSL Limited Systemic Sclerosis Drug Product Portfolio
  48. 8.8.5 CSL Limited Recent Developments
  49. 8.9 Corbus pharmaceuticals, Inc.
  50. 8.9.1 Corbus pharmaceuticals, Inc. Company Information
  51. 8.9.2 Corbus pharmaceuticals, Inc. Business Overview
  52. 8.9.3 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Corbus pharmaceuticals, Inc. Systemic Sclerosis Drug Product Portfolio
  54. 8.9.5 Corbus pharmaceuticals, Inc. Recent Developments
  55. 8.10 Bristol-Myers Squibb Company
  56. 8.10.1 Bristol-Myers Squibb Company Company Information
  57. 8.10.2 Bristol-Myers Squibb Company Business Overview
  58. 8.10.3 Bristol-Myers Squibb Company Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Company Systemic Sclerosis Drug Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Company Recent Developments
  61. 8.11 Boehringer Ingelheim GmbH
  62. 8.11.1 Boehringer Ingelheim GmbH Company Information
  63. 8.11.2 Boehringer Ingelheim GmbH Business Overview
  64. 8.11.3 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim GmbH Systemic Sclerosis Drug Product Portfolio
  66. 8.11.5 Boehringer Ingelheim GmbH Recent Developments
  67. 8.12 BiOrion Technologies B.V.
  68. 8.12.1 BiOrion Technologies B.V. Company Information
  69. 8.12.2 BiOrion Technologies B.V. Business Overview
  70. 8.12.3 BiOrion Technologies B.V. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BiOrion Technologies B.V. Systemic Sclerosis Drug Product Portfolio
  72. 8.12.5 BiOrion Technologies B.V. Recent Developments
  73. 8.13 BioLineRx, Ltd.
  74. 8.13.1 BioLineRx, Ltd. Company Information
  75. 8.13.2 BioLineRx, Ltd. Business Overview
  76. 8.13.3 BioLineRx, Ltd. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 BioLineRx, Ltd. Systemic Sclerosis Drug Product Portfolio
  78. 8.13.5 BioLineRx, Ltd. Recent Developments
  79. 8.14 arGentis Pharmaceuticals, LLC
  80. 8.14.1 arGentis Pharmaceuticals, LLC Company Information
  81. 8.14.2 arGentis Pharmaceuticals, LLC Business Overview
  82. 8.14.3 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 arGentis Pharmaceuticals, LLC Systemic Sclerosis Drug Product Portfolio
  84. 8.14.5 arGentis Pharmaceuticals, LLC Recent Developments
  85. 8.15 Angion Biomedica Corp.
  86. 8.15.1 Angion Biomedica Corp. Company Information
  87. 8.15.2 Angion Biomedica Corp. Business Overview
  88. 8.15.3 Angion Biomedica Corp. Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Angion Biomedica Corp. Systemic Sclerosis Drug Product Portfolio
  90. 8.15.5 Angion Biomedica Corp. Recent Developments
  91. 8.16 Allergan Plc
  92. 8.16.1 Allergan Plc Company Information
  93. 8.16.2 Allergan Plc Business Overview
  94. 8.16.3 Allergan Plc Systemic Sclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Allergan Plc Systemic Sclerosis Drug Product Portfolio
  96. 8.16.5 Allergan Plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Systemic Sclerosis Drug Value Chain Analysis
  2. 9.1.1 Systemic Sclerosis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Systemic Sclerosis Drug Production Mode & Process
  6. 9.2 Systemic Sclerosis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Systemic Sclerosis Drug Distributors
  9. 9.2.3 Systemic Sclerosis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst